Mountain Pacific Investment Advisers LLC Buys 853 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Mountain Pacific Investment Advisers LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 42,611 shares of the medical research company’s stock after buying an additional 853 shares during the period. Thermo Fisher Scientific comprises 1.6% of Mountain Pacific Investment Advisers LLC’s portfolio, making the stock its 28th biggest holding. Mountain Pacific Investment Advisers LLC’s holdings in Thermo Fisher Scientific were worth $22,168,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Legacy Investment Solutions LLC bought a new position in shares of Thermo Fisher Scientific during the 3rd quarter worth about $26,000. Peterson Financial Group Inc. bought a new position in Thermo Fisher Scientific in the 3rd quarter valued at $27,000. Decker Retirement Planning Inc. bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth $43,000. HWG Holdings LP acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $50,000. Finally, RPg Family Wealth Advisory LLC bought a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at about $50,000. 89.23% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This trade represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the completion of the sale, the executive vice president now owns 16,663 shares of the company’s stock, valued at $9,333,946.08. This trade represents a 1.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,150 shares of company stock valued at $25,954,465 over the last ninety days. 0.34% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TMO shares. Redburn Atlantic started coverage on shares of Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective on the stock. Morgan Stanley cut their target price on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a research note on Monday, January 13th. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Finally, Royal Bank of Canada lowered their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $648.95.

Thermo Fisher Scientific Stock Performance

NYSE TMO opened at $559.72 on Tuesday. The firm’s fifty day moving average price is $529.96 and its two-hundred day moving average price is $568.56. Thermo Fisher Scientific Inc. has a 1 year low of $493.30 and a 1 year high of $627.88. The firm has a market capitalization of $214.09 billion, a P/E ratio of 35.09, a price-to-earnings-growth ratio of 3.71 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. During the same quarter in the previous year, the business earned $5.69 earnings per share. The business’s revenue was up .2% compared to the same quarter last year. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were issued a $0.39 dividend. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.